- Lunit's AI-powered chest X-ray analysis solution shows highest AUC of 0.93 in a recent multi-cent...
* Three-year supply contract: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage to enhance lung abn...
- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisionin...
* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's Bre...
* Lunit INSIGHT CXR is piloted at Singapore General Hospital and Changi General Hospital through...
* AI-powered spatial analysis of tumor-infiltrating lymphocytes using Lunit SCOPE IO provides acc...
- A large population-based retrospective study in Denmark validates that Lunit INSIGHT MMG's accura...
- Lunit brings Lunit INSIGHT CXR to five major Saudi hospitals, aiming to enhance early detectio...
* Fund fully paid-in as of November 9, achieving over 100% shareholder participation SEOUL, South...
- Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT market ...
- Lunit INSIGHT suite, Lunit's AI-driven solutions for early detection of cancer, featured in Cance...
* Two oral presentations and five ePosters accepted by the RSNA: presenting AI advancements for c...
* Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment ar...
- Lunit joins as an Associate Partner of the World Economic Forum, propelling global expansion and ...
- Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembroliz...
* Memorandum of Understanding to be inked between Lunit and Seha Virtual Hospital, marking a new ...
* Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunother...
- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker ...
- 9 abstracts accepted by the ESMO annual meeting - unveiling insights into cancer analysis, immuno...
- Lunit's 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SC...
